DK158994C - Analogifremgangsmaade til fremstilling af enzymderivater indeholdende et streptokinase/plasminogen-kompleks - Google Patents

Analogifremgangsmaade til fremstilling af enzymderivater indeholdende et streptokinase/plasminogen-kompleks

Info

Publication number
DK158994C
DK158994C DK468880A DK468880A DK158994C DK 158994 C DK158994 C DK 158994C DK 468880 A DK468880 A DK 468880A DK 468880 A DK468880 A DK 468880A DK 158994 C DK158994 C DK 158994C
Authority
DK
Denmark
Prior art keywords
striptkinase
derivatives containing
analogy procedure
preparing enzyme
enzyme derivatives
Prior art date
Application number
DK468880A
Other languages
English (en)
Other versions
DK158994B (da
DK468880A (da
Inventor
Richard Anthony Godwin Smith
John Gordon Winchester
Original Assignee
Beecham Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beecham Group Ltd filed Critical Beecham Group Ltd
Publication of DK468880A publication Critical patent/DK468880A/da
Publication of DK158994B publication Critical patent/DK158994B/da
Application granted granted Critical
Publication of DK158994C publication Critical patent/DK158994C/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3153—Streptokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/99—Enzyme inactivation by chemical treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK468880A 1979-11-05 1980-11-04 Analogifremgangsmaade til fremstilling af enzymderivater indeholdende et streptokinase/plasminogen-kompleks DK158994C (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB7938279 1979-11-05
GB7938279 1979-11-05

Publications (3)

Publication Number Publication Date
DK468880A DK468880A (da) 1981-05-06
DK158994B DK158994B (da) 1990-08-13
DK158994C true DK158994C (da) 1991-01-07

Family

ID=10508982

Family Applications (1)

Application Number Title Priority Date Filing Date
DK468880A DK158994C (da) 1979-11-05 1980-11-04 Analogifremgangsmaade til fremstilling af enzymderivater indeholdende et streptokinase/plasminogen-kompleks

Country Status (18)

Country Link
US (1) US4808405A (da)
EP (1) EP0028489B1 (da)
JP (1) JPS5678590A (da)
AR (1) AR224786A1 (da)
CA (1) CA1174621A (da)
CS (2) CS391191A3 (da)
DE (1) DE3065190D1 (da)
DK (1) DK158994C (da)
ES (1) ES8204467A1 (da)
GR (1) GR72121B (da)
HK (1) HK65886A (da)
HU (1) HU185223B (da)
IE (1) IE50174B1 (da)
IL (1) IL61408A (da)
NL (1) NL930029I2 (da)
NO (1) NO163867C (da)
NZ (1) NZ195469A (da)
ZA (1) ZA806641B (da)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3361610D1 (en) * 1982-04-07 1986-02-06 Beecham Group Plc Enzyme derivatives, process for preparing them and pharmaceutical compositions containing them
WO1984001960A1 (en) * 1982-11-11 1984-05-24 Beecham Group Plc Pharmaceutically active compounds
GB8400653D0 (en) * 1984-01-11 1984-02-15 Beecham Group Plc Conjugates
GB8430253D0 (en) * 1984-11-30 1985-01-09 Beecham Group Plc Compounds
US5231006A (en) * 1986-10-16 1993-07-27 Behringwerke Aktiengesellschaft Method for the determination of plasminogen
US5256642A (en) * 1988-04-01 1993-10-26 The Johns Hopkins University Compositions of soluble complement receptor 1 (CR1) and a thrombolytic agent, and the methods of use thereof
JPH0296536A (ja) * 1988-09-29 1990-04-09 Green Cross Corp:The プラスミノゲン乾燥製剤
WO1990013640A1 (en) * 1989-05-01 1990-11-15 The University Of Notre Dame Du Lac Methods and materials for expression of human plasminogen in a eukaryotic cell system
EP0397366A1 (en) * 1989-05-09 1990-11-14 The Board Of Regents Of The University Of Oklahoma Hybrid streptokinases with fibrin binding domains and methods for the synthesis of same
WO1990014078A1 (en) * 1989-05-17 1990-11-29 Research Corporation Technologies, Inc. Method and composition for the treatment of thrombosis in a mammal
AU6470590A (en) 1989-10-23 1991-04-26 Smithkline Beecham Corporation Cyclic anti-aggregatory peptides
US5087572A (en) * 1989-12-01 1992-02-11 Genentech, Inc. Dna encoding human plasminogen modified at the cleavage site
US5190756A (en) * 1989-12-01 1993-03-02 Genentech, Inc. Methods and materials for expression of human plasminogen variant
GB8928163D0 (en) * 1989-12-13 1990-02-14 Beecham Group Plc Novel treatment
US6458360B1 (en) 1990-04-25 2002-10-01 The Johns Hopkins University Soluble complement regulatory molecules
US5187069A (en) * 1990-08-06 1993-02-16 Henry Ford Health System Active site labelling of plasminogen
WO1992018139A1 (en) * 1991-04-09 1992-10-29 Brigham And Women's Hospital Chimeric molecule with plasminogen activator activity and affinity for atherosclerotic plaques
US5520912A (en) * 1993-07-02 1996-05-28 Immuno Aktiengesellschaft Prevention and treatment of ischemic events and reperfusion injury resulting therefrom using lys-plasminogen
DE4411143C2 (de) * 1994-03-30 1996-08-01 Immuno Ag Thrombosemittel
US5760028A (en) * 1995-12-22 1998-06-02 The Dupont Merck Pharmaceutical Company Integrin receptor antagonists
US6004955A (en) * 1996-08-15 1999-12-21 Dupont Pharmaceuticals Company Cyclic carbamates and isoxazolidines as IIb/IIIa antagonists
HRP980334A2 (en) 1997-06-19 1999-04-30 Mimi Lifen Quan INHIBITORS OF FACTOR Xa WITH A NEUTRAL P1 SPECIFICITY GROUP
CA2376245A1 (en) * 1999-07-29 2001-02-08 Dyax Corp. Binding moieties for fibrin
US6388073B1 (en) 2000-07-26 2002-05-14 Shire Us Inc. Method for the manufacture of anagrelide
KR20010000669A (ko) * 2000-10-12 2001-01-05 김기환 스트렙토키나제와 사람 혈청알부민의 포합체를유효성분으로 함유하는 전신투여용 지속성 혈전 용해제
US6984373B2 (en) * 2000-12-23 2006-01-10 Dyax Corp. Fibrin binding moieties useful as imaging agents
EP1427415B1 (en) 2001-09-21 2009-08-12 Brystol-Myers Squibb Company Lactam-containing compounds and derivatives thereof as factor xa inhibitors
US7550499B2 (en) 2004-05-12 2009-06-23 Bristol-Myers Squibb Company Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
US7700608B2 (en) * 2004-08-04 2010-04-20 Shire Holdings Ag Quinazoline derivatives and their use in the treatment of thrombocythemia
US20060030574A1 (en) * 2004-08-04 2006-02-09 Shire Holdings Ag Quinazoline derivatives useful for the treatment of peripheral arterial disease and as phosphodiesterase inhibitors
JP5236293B2 (ja) 2005-01-13 2013-07-17 ブリストル−マイヤーズ スクイブ カンパニー Ｘｉａ因子阻害剤としての置換ビアリール化合物
AU2006206611A1 (en) 2005-01-19 2006-07-27 Bristol-Myers Squibb Company 2-phenoxy-N- (1, 3 , 4-thiadizol-2-yl) pyridin-3-amine derivatives and related compounds as P2Y1 receptor inhibitors for the treatment of thromboembolic disorders
DE602006020871D1 (de) 2005-06-27 2011-05-05 Bristol Myers Squibb Co Lineare harnstoffmimetika-antagonisten des p2y1-rezeptors zur behandlung von thromboseleiden
US7728008B2 (en) 2005-06-27 2010-06-01 Bristol-Myers Squibb Company N-linked heterocyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
US7714002B2 (en) 2005-06-27 2010-05-11 Bristol-Myers Squibb Company Carbocycle and heterocycle antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
WO2007002635A2 (en) 2005-06-27 2007-01-04 Bristol-Myers Squibb Company C-linked cyclic antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
WO2007146719A2 (en) 2006-06-08 2007-12-21 Bristol-Myers Squibb Company 2-aminocarbonylphenylamino-2-phenylacetamides as factor viia inhibitors useful as anticoagulants
US7960569B2 (en) 2006-10-17 2011-06-14 Bristol-Myers Squibb Company Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
US8304420B2 (en) 2006-11-28 2012-11-06 Shire Llc Substituted quinazolines for reducing platelet count
US7910597B2 (en) * 2006-11-28 2011-03-22 Shire Llc Substituted quinazolines
EP2102189B1 (en) 2006-12-15 2015-07-29 Bristol-Myers Squibb Company Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor xia inhibitors
PE20081775A1 (es) 2006-12-20 2008-12-18 Bristol Myers Squibb Co Compuestos macrociclicos como inhibidores del factor viia
EP2152664B1 (en) 2007-06-13 2014-09-03 Bristol-Myers Squibb Company Dipeptide analogs as coagulation factor inhibitors
US20090130017A1 (en) * 2007-11-19 2009-05-21 Searete Llc Targeted short-lived drug delivery
CN102099340A (zh) 2008-05-19 2011-06-15 先灵公司 作为因子ixa抑制剂的杂环化合物
SMT202000093T1 (it) 2009-06-16 2020-03-13 Pfizer Forme di dosaggio di apixaban
WO2011017296A1 (en) 2009-08-04 2011-02-10 Schering Corporation 4, 5, 6-trisubstituted pyrimidine derivatives as factor ixa inhibitors
CA2789622C (en) 2010-02-11 2018-04-03 Bristol-Myers Squibb Company Macrocycles as factor xia inhibitors
TW201311689A (zh) 2011-08-05 2013-03-16 必治妥美雅史谷比公司 作為因子ｘｉａ抑制劑之新穎巨環化合物
TW201319068A (zh) 2011-08-05 2013-05-16 必治妥美雅史谷比公司 作為ｘｉａ因子抑制劑之環狀ｐ１接合劑
WO2013056034A1 (en) 2011-10-14 2013-04-18 Bristol-Myers Squibb Company Substituted tetrahydroisoquinoline compounds as factor xia inhibitors
SI2766346T1 (sl) 2011-10-14 2017-05-31 Bristol-Myers Squibb Company Substituirane tetrahidroizokinolinske spojine kot faktor xia inhibitorji
EP2899183B1 (en) 2011-10-14 2018-09-19 Bristol-Myers Squibb Company Substituted Tetrahydroisoquinoline Compounds as Factor Xia Inhibitors
GEP201706656B (en) 2011-11-11 2017-04-25 Pfizer 2-thiopyrimidinones
SG11201405477XA (en) 2012-04-06 2014-11-27 Pfizer Diacylglycerol acyltransferase 2 inhibitors
LT2882734T (lt) 2012-08-03 2016-12-12 Bristol-Myers Squibb Company Dihidropiridonai, kaip xia faktoriaus slopikliai
PT2880026T (pt) 2012-08-03 2017-05-03 Bristol Myers Squibb Co Dihidropiridona p1 como inibidores de fator xia
EP2978751B1 (en) 2013-03-25 2018-12-05 Bristol-Myers Squibb Company Tetrahydroisoquinolines containing substituted azoles as factor xia inhibitors
JP6348582B2 (ja) 2013-10-09 2018-06-27 ファイザー・インク プロスタグランジンｅｐ３受容体の拮抗薬
NO2760821T3 (da) 2014-01-31 2018-03-10
KR20240017118A (ko) 2014-01-31 2024-02-06 브리스톨-마이어스 스큅 컴퍼니 인자 XIa 억제제로서의 헤테로시클릭 P2' 기를 갖는 마크로사이클
EP3119757B1 (en) 2014-03-17 2018-05-16 Pfizer Inc Diacylglycerol acyltransferase 2 inhibitors for use in the treatment of metabolic and related disorders
WO2015150995A1 (en) 2014-04-04 2015-10-08 Pfizer Inc. Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors
WO2015160636A1 (en) 2014-04-16 2015-10-22 Merck Sharp & Dohme Corp. Factor ixa inhibitors
NO2721243T3 (da) 2014-10-01 2018-10-20
MA42035A (fr) 2015-05-05 2018-03-14 Pfizer 2-thiopyrimidinones
ES2832893T3 (es) 2015-06-17 2021-06-11 Pfizer Compuestos tricíclicos y su uso como inhibidores de la fosfodiesterasa
WO2016203335A1 (en) 2015-06-18 2016-12-22 Pfizer Inc. Novel pyrido[2,3-b]pyrazinones as bet-family bromodomain inhibitors
US10676477B2 (en) 2015-07-29 2020-06-09 Bristol-Myers Squibb Company Factor XIa macrocycle inhibitors bearing a non-aromatic P2' group
CN108137549B (zh) 2015-08-05 2021-07-20 百时美施贵宝公司 取代的甘氨酸衍生的fxia抑制剂
RS61719B1 (sr) 2015-08-27 2021-05-31 Pfizer Biciklična fuzionisana hetaroaril ili aril jedinjenja kao modulatori irak4
WO2017151746A1 (en) 2016-03-02 2017-09-08 Bristol-Myers Squibb Company Diamide macrocycles having factor xia inhibiting activity
AR109179A1 (es) 2016-08-19 2018-11-07 Pfizer Inhibidores de diacilglicerol aciltransferasa 2
BR112021003039A2 (pt) 2018-08-31 2021-05-18 Pfizer Inc. combinações para o tratamento de nash/nafld e doenças relacionadas
US12611401B2 (en) 2019-05-20 2026-04-28 Pfizer Inc. Combinations comprising benzodioxol as GLP-1R agonists for use in the treatment of NASH/NAFLD and related diseases
ES3048448T3 (en) 2020-07-22 2025-12-10 Janssen Pharmaceutica Nv Compounds useful as factor xia inhibitors
WO2023026180A1 (en) 2021-08-26 2023-03-02 Pfizer Inc. Amorphous form of (s)-2-(5-((3-ethoxypyridin-2-yl)oxy)pyridin-3-yl)-n-(tetrahydrofuran-3- yl)pyrimidine-5-carboxamide
WO2024118524A1 (en) 2022-11-28 2024-06-06 Cerevel Therapeutics, Llc Azaindole compounds and their use as phosphodiesterase inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4178368A (en) * 1971-09-30 1979-12-11 Behringwerke Aktiengesellschaft Method for the treatment of thromboembolism
JPS5325775A (en) * 1976-08-24 1978-03-09 Miller Fluid Power Corp Module type fluid flow control element
US4082612A (en) * 1976-09-24 1978-04-04 Michael Reese Research Foundation Plasminogen activator complex
NZ191320A (en) * 1978-09-07 1982-09-14 Beecham Group Ltd In vivo fibrinolytic enzyme having active site blocked by hydrolytically removable group pharmaceutical compositions

Also Published As

Publication number Publication date
AU6401180A (en) 1981-05-14
HK65886A (en) 1986-09-12
CS391191A3 (en) 1992-08-12
ES496586A0 (es) 1982-05-01
AR224786A1 (es) 1982-01-15
JPS5678590A (en) 1981-06-27
CS391991A3 (en) 1992-06-17
CA1174621A (en) 1984-09-18
JPH0316114B2 (da) 1991-03-04
ZA806641B (en) 1981-10-28
NO803304L (no) 1981-05-06
NO163867B (no) 1990-04-23
AU534017B2 (en) 1983-12-22
IL61408A0 (en) 1980-12-31
NL930029I1 (nl) 1993-06-01
NZ195469A (en) 1984-05-31
NL930029I2 (nl) 1993-12-01
US4808405A (en) 1989-02-28
IE802277L (en) 1981-05-05
IE50174B1 (en) 1986-02-19
ES8204467A1 (es) 1982-05-01
NO163867C (no) 1990-08-01
DK158994B (da) 1990-08-13
EP0028489B1 (en) 1983-10-05
HU185223B (en) 1984-12-28
GR72121B (da) 1983-09-16
EP0028489A1 (en) 1981-05-13
IL61408A (en) 1983-10-31
DE3065190D1 (en) 1983-11-10
DK468880A (da) 1981-05-06

Similar Documents

Publication Publication Date Title
DK468880A (da) Fremgangsmaade til fremstilling af enzymderivater
DK300177A (da) Fremgangsmade til fremstilling af et enzymgranulat
DK157019C (da) Analogifremgangsmaade til fremstilling af 2-amino-4-hydroxyquinazolinderivater
DK458679A (da) Fremgangsmaade til fremstilling af nitrogenholdige heterocycliske forbindelser
DK152138C (da) Fremgangsmaade til fremstilling af urokinase
DK157169C (da) Fremgangsmaade til fremstilling af et koncentrat af prothrombinkompleks
DK145698C (da) Analogifremgangsmaade til fremstilling af 2-alkoxyadeninderivater
DK453080A (da) Fremgangsmaade til fremstilling af et depllymeriserende enzym
DK147145C (da) Analogifremgangsmaade til fremstilling af chlorambucilderivater
DK138879A (da) Fremgangsmaade til fremstilling af lysergolderivater
DK289580A (da) Fremgangsmaade til fremstilling af heterocycliske phenoxyaminer
DK512379A (da) Fremgangsmaade til chlorering af pyridinderivater
DK387480A (da) Fremgangsmaade til fremstilling af 2-alkyl-eller 2-aryithiomethylphenoler
DK154136C (da) Analogifremgangsmaade til fremstilling af 2-amino-3-benzoylphenylacetamider
DK135480A (da) Fremgangsmaade til fremstilling af 2-(2-pyridyl)-tetrahydrothiopen-derivater
DK355180A (da) Fremgangsmaade til fremstilling af heterocycliske forbindelser
DK255279A (da) Piperidinderivater af 1,3,5-triazoxycloheptan-2,4-dion samt fremgangsmaade til fremstilling og anvendelse af disse
DK493780A (da) Fremgangsmaade til fremstilling af et nicotinamidderivat
DK134880A (da) Fremgangsmaade til fremstilling af benzothiazolderivater fremgangsmaade til fe
DK183780A (da) Femgangsmaade til fremstilling af hydroxyderivater af isopropylaminopyrimidin
DK56480A (da) Fremgangsmaade til fremstilling af et kombinationsemne
DK197477A (da) Fremgangsmade til fremstilling af et lipaserigt enzympreparat
DK159878A (da) Fremgangsmaade til fremstilling af urokinase
DK569078A (da) Fremgangsmaade til fremstilling af nye arylaminoimidazolinderivater
DK239080A (da) Fremgangsmaade til modificering af azopigmenter

Legal Events

Date Code Title Description
PBP Patent lapsed